id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2020-P-1633-0006,FDA,FDA-2020-P-1633,Final Response Letter from FDA CBER to Foley Hoag LLP on behalf of the Microbiome Therapeutics Innovation Group,Other,Letter(s),2022-11-29T05:00:00Z,2022,11,2022-11-29T05:00:00Z,,2022-11-29T21:10:28Z,,0,0,0900006485509160
FDA-2020-P-1633-0005,FDA,FDA-2020-P-1633,"Interim Response Letter from FDA CBER to Foley Hoag, LLP (on behalf of the Microbiome Therapeutics Innovation Group)",Other,Letter(s),2020-12-29T05:00:00Z,2020,12,2020-12-29T05:00:00Z,,2020-12-29T20:33:10Z,,0,0,09000064849d0105
FDA-2020-P-1633-0003,FDA,FDA-2020-P-1633,"Exhibit A - Clinical trials for treatment and prevention of C_ difficile disease re Citizen Petition from Foley Hoag, LLP (on behalf of the Microbiome Therapeutics Innovation Group)",Supporting & Related Material,Background Material,2020-07-06T04:00:00Z,2020,7,,,2020-07-08T17:30:33Z,,0,0,09000064847281dd
FDA-2020-P-1633-0001,FDA,FDA-2020-P-1633,"Citizen Petition from Foley Hoag, LLP (on behalf of the Microbiome Therapeutics Innovation Group)",Other,Citizen Petition,2020-07-06T04:00:00Z,2020,7,2020-07-06T04:00:00Z,,2022-11-29T21:04:57Z,,0,0,09000064847281d9
FDA-2020-P-1633-0002,FDA,FDA-2020-P-1633,"Acknowledgment Letter from FDA DMS to Foley Hoag, LLP (on behalf of the Microbiome Therapeutics Innovation Group)",Other,Acknowledgement Letter/Receipt,2020-07-06T04:00:00Z,2020,7,2020-07-06T04:00:00Z,,2020-07-08T17:30:04Z,,0,0,09000064847281da